Table 3.
Emerging immunotherapeutic to treatment of metastatic melanoma.
| Target | Drug | Class | Phase(s) trial | Protocol_IDs* |
|---|---|---|---|---|
| CD40 | CP-870,893 | Fully human mAb | I | NCT01008527 |
| I | NCT01103635 | |||
| CD137 | BMS-663513 | mAb | I | NCT00803374 |
| Cytokines | Interleukin-21 | Recombinant human molecule | II | NCT01152788 |
| CTLA-4 | Tremelimumab | Fully human IgG2 mAb | III | [62] |
| II | NCT01034787 | |||
| Immunocytokines | EMD 273063 | Humanized anti-GD2 mAb linked to IL-2 | II | NCT00590824 |
| α v integrin | CNTO95 | mAb | I, II | NCT00246012 |
| α v β 3 integrin | MEDI-522 | Humanized mAb | I | NCT00111696 |
| PD1 | MDX-1106 | Fully human mAb | I | NCT00730639 |
| I | NCT01024231 | |||
| I | NCT01176461 | |||
| TGF-β | GC1008 | Fully human mAb | I | NCT00899444 |
| TGF-β2 | AP12009 | Antisense oligonucleotide | I | NCT00844064 |
| TLR regulation of Treg cells | CpG 7909 (ProMune) | Synthetic oligonucleotide | II | NCT01266603 |
| No phase specified | NCT00471471 |
*Randomized clinical trials selected from http://www.clinicaltrials.gov/.